Apr 302014
Regulators in Europe have given the green light to GlaxoSmithKline’s new chronic obstructive pulmonary disease drug Incruse.
Specifically, the European Commission has granted marketing authorisation for Incruse (umeclidinium) as a once-daily treatment to relieve symptoms in adults with COPD. The drug is a once-daily long-acting muscarinic antagonist (LAMA) delivered by GSK’s Ellipta inhaler.
Read more at: http://www.pharmatimes.com/Article/14-04-28/Europe_green_light_for_GSK_COPD_drug.aspx#ixzz30Lohff26
Follow us: @PharmaTimes on Twitter
read
http://www.pharmatimes.com/Article/14-04-28/Europe_green_light_for_GSK_COPD_drug.aspx
Sorry, the comment form is closed at this time.